Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects

NCT01445301 | Completed Phase 3 Results

• 1 other identifier: 115287
• Study Type: interventional
• Target: 800
• Locations: 1 country
• Sites: 26

Brief Summary

This is a multicenter, randomized, single-blinded (investigator's blinded), active-controlled (clindamycin \[CLDM\] 1% gel), parallel-group study in Japanese subjects with acne vulgaris to demonstrate the efficacy of GSK2585823 (CLDM 1%-benzoyl peroxide \[BPO\] 3% gel) when applied once or twice daily for 12 weeks. This study will also evaluate the safety of GSK2585823 when applied topically either once or twice daily for 12 weeks.

Conditions

Acne Vulgaris

Keywords

twice daily; once daily; CLDM 1%-BPO 3% gel; Clindamycin (CLDM); benzoyl peroxide (BPO); inflammatory lesion; non-inflammatory lesion; acne vulgaris

Outcome Measures

Primary Outcomes (1)

• Absolute Change From Baseline to Week 12 in Total Lesion Counts.

  The investigator (or subinvestigator) counted all inflammatory lesions (papules, pustules, and nodular lesions) and non-inflammatory lesions (open and closed comedones) on the face at each study visit. An open comedone was an open, widely dilated follicle with black-colored sebum, due to melanin and oxidation, and keratinous material that forms a plug, thereby obstructing the pilosebaceous duct. A closed comedone was a closed follicle filled with impacted sebum covered by keratin that has a whitish color. A papule was a small, raised, red, dome-shaped palpable lesion. A pustule was a raised, dome-shaped palpable lesion containing yellow fluid (pus). A nodule might be a raised or deep-seated, dome-shaped palpable lesion of at least 5 millimeters in diameter. Day 1 was Baseline and change from baseline was calculated by subtracting the Baseline value from post-randomization value at Week 12.

  Baseline (Day 1) and Week 12

Secondary Outcomes (9)

• Absolute Change From Baseline to Weeks 1, 2, 4, and 8 in Total Lesion Counts

  Baseline (Day 1) and Weeks 1, 2, 4, and 8

• Absolute Change From Baseline to Weeks 1, 2, 4, 8, and 12 in Inflammatory and Non-inflammatory Lesion Counts

  Baseline (Day 1) and Weeks 1, 2, 4, 8, and 12

• Percent Change From Baseline to Weeks 1, 2, 4, 8, and 12 in Total, Inflammatory, and Non- Inflammatory Lesion Counts

  Baseline (Day 1) and Weeks 1, 2, 4, 8, and 12

• Percentage of Participants With a Minimum 2-grade Improvement From Baseline to Week 12 in Investigator's Static Global Assessment (ISGA) Score

  Baseline (Day 1) and Week 12

• Percentage of Participants With an ISGA Score of 0 (Clear) or 1 (Almost Clear) at Weeks 1, 2, 4, 8, and 12

  Week 1, 2, 4, 8, and 12

Study Arms (3)

GSK2585823(CLDM 1%-BPO 3% gel) once daily

EXPERIMENTAL

Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be once daily in the evening/bedtime.

Drug: GSK2585823(CLDM 1%-BPO 3% gel)

GSK2585823(CLDM 1%-BPO 3% gel) twice daily

EXPERIMENTAL

Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be twice daily in the morning and evening/bedtime.

Drug: GSK2585823(CLDM 1%-BPO 3% gel)

CLDM 1% gel twice daily

ACTIVE COMPARATOR

Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be twice daily in the morning and evening/bedtime.

Drug: CLDM 1% gel twice daily

Interventions

GSK2585823(CLDM 1%-BPO 3% gel) DRUG

Topical gel in 1 g containing clindamycin 10 mg and benzoyl peroxide 30 mg

Also known as: GSK2585823

GSK2585823(CLDM 1%-BPO 3% gel) once daily; GSK2585823(CLDM 1%-BPO 3% gel) twice daily

CLDM 1% gel twice daily DRUG

Topical gel containing clindamycin 10 mg/1 g gel

Also known as: CLDM

CLDM 1% gel twice daily

Eligibility Criteria

• Age: 12 Years - 45 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Male or female subjects 12 to 45 years (inclusive) of age in good general health.
• Subjects must have both on the face:
• A) A minimum of 17 but not more than 60 inflammatory lesions (papules/pustules), including nasal lesions.
• And B) A minimum of 20 but not more than 150 non-inflammatory lesions (open/closed comedones), including nasal lesions.
• An ISGA score of 2 or greater at baseline.
• Females of childbearing potential and women who are less than 2 years from their last menses must agree to use the contraception.
• The ability and willingness to follow all study procedures and attend all scheduled visits.
• The ability to understand and sign a written informed consent form (Written informed consent must be obtained also from the parent or guardian in case of subject under 20 years of age at the time of given consent).

You may not qualify if:

• Have any nodule-cystic lesions at baseline.
• Are pregnant or breast-feeding.
• Have a history or presence of regional enteritis, inflammatory bowel disease (e.g., ulcerative colitis, pseudomembranous colitis, chronic diarrhea or antibiotic-associated colitis) or similar symptoms.
• Used any of the following agents on the face within the previous 2 weeks:Topical antibiotics (or systemic antibiotics);Topical anti-acne medications (e.g., BPO, azelaic acid, resorcinol, salicylates);Abradants, facials, or peels containing glycolic or other acids;Masks, washes or soaps containing BPO, sulfacetamide sodium, or salicylic acid;Non-mild facial cleansers (e.g., facial scrub, cleansers containing agents with anti-inflammatory action); Moisturizers that contain retinol, salicylic acid, or α- or β-hydroxy acids;Astringents and toner (Subjects are allowed to enroll in this study, if the subject has been on treatment for more than 2 consecutive weeks prior to start of investigational product use).
• Used the following agents on the face or performed the following procedure within the previous 4 weeks:Topical corticosteroids (Use of inhaled, intra-articular, or intra-lesional steroids other than for facial acne is acceptable);Facial procedure (such as chemical or laser peel, microdermabrasion, blue light treatment, etc.).
• Used systemic retinoids within the previous 6 months or topical retinoids on the face within the previous 6 weeks.
• Received treatment with estrogens, androgens, or anti-androgenic agents within the previous 12 weeks (Subjects who have been treated with the above agents for more than 12 consecutive weeks prior to start of investigational product are allowed to enrol as long as they do not expect to change dose, drug, or discontinue use during the study).
• Used any medication that in the opinion of the investigator may affect this clinical study or evaluation of the study.
• Plan to use medications that are reported to exacerbate acne (e.g., mega-doses of certain vitamins, such as vitamin D \[\>2000 IU/day\] and vitamin B12 \[\>1 mg/day\], corticosteroids\*, androgens, haloperidol, halogens \[e.g., iodide and bromide\], lithium, hydantoin, and phenobarbital).
• \*: except the using of topical corticosteroids (e.g., inhaled, intra-articular, or intra-lesional steroids) other than for facial acne.
• Have a known hypersensitivity or have had previous allergic reaction to any of the components of the investigational product.
• Used any investigational therapy within the previous 12 weeks, or plan to participate in another clinical study at the same time.
• Participated in Japanese clinical studies planned by GlaxoSmithKline K.K. in the development of investigational products for acne vulgaris.
• Are currently abusing drugs or alcohol.
• Have a significant medical history of being immunocompromised.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (26)

GSK Investigational Site

Chiba, 273-0046, Japan

Location

GSK Investigational Site

Hokkaido, 002-8022, Japan

Location

GSK Investigational Site

Hokkaido, 003-0833, Japan

Location

GSK Investigational Site

Hokkaido, 004-0074, Japan

Location

GSK Investigational Site

Hokkaido, 004-0876, Japan

Location

GSK Investigational Site

Hokkaido, 006-0022, Japan

Location

GSK Investigational Site

Hokkaido, 060-0063, Japan

Location

GSK Investigational Site

Hokkaido, 062-0042, Japan

Location

GSK Investigational Site

Hokkaido, 064-0915, Japan

Location

GSK Investigational Site

Hokkaido, 066-0021, Japan

Location

GSK Investigational Site

Hokkaido, 066-0064, Japan

Location

GSK Investigational Site

Hokkaido, 069-0813, Japan

Location

GSK Investigational Site

Hokkaido, 090-0832, Japan

Location

GSK Investigational Site

Hokkaido, 093-0016, Japan

Location

GSK Investigational Site

Kanagawa, 211-0063, Japan

Location

GSK Investigational Site

Kanagawa, 221-0825, Japan

Location

GSK Investigational Site

Osaka, 532-0026, Japan

Location

GSK Investigational Site

Osaka, 559-0017, Japan

Location

GSK Investigational Site

Osaka, 572-0838, Japan

Location

GSK Investigational Site

Osaka, 593-8324, Japan

Location

GSK Investigational Site

Saitama, 350-1305, Japan

Location

GSK Investigational Site

Tokyo, 111-0053, Japan

Location

GSK Investigational Site

Tokyo, 141-0031, Japan

Location

GSK Investigational Site

Tokyo, 150-0021, Japan

Location

GSK Investigational Site

Tokyo, 169-0075, Japan

Location

GSK Investigational Site

Tokyo, 194-0013, Japan

Location

MeSH Terms

Conditions

Acne Vulgaris

Interventions

Gels

Condition Hierarchy (Ancestors)

Acneiform Eruptions; Skin Diseases; Skin and Connective Tissue Diseases; Sebaceous Gland Diseases

Intervention Hierarchy (Ancestors)

Colloids; Complex Mixtures; Dosage Forms; Pharmaceutical Preparations

Results Point of Contact

• Title: GSK Response Center
• Organization: GlaxoSmithKline

866-435-7343

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 15, 2011
• First Posted: October 3, 2011
• Study Start: September 27, 2011
• Primary Completion: August 2, 2012
• Study Completion: August 2, 2012
• Last Updated: April 27, 2018
• Results First Posted: April 27, 2018

Record last verified: 2017-09

Locations

JP (26)